Biomarin Pharmaceutical Inc. Revenue 2008–2025
Biomarin Pharmaceutical Inc. annual/quarterly revenue history and growth rate from 2008 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Biomarin Pharmaceutical Inc. revenue for the quarter ending March 31, 2026 was 766.2 M, a 2.83% increase year-over-year.
- Biomarin Pharmaceutical Inc. revenue for the twelve months ending March 31, 2026 was 3.1 B, a 15.81% increase year-over-year.
- Biomarin Pharmaceutical Inc. annual revenue for 2025 was 3.2 B, a 12.87% increase from 2024.
- Biomarin Pharmaceutical Inc. annual revenue for 2024 was 2.9 B, a 17.97% increase from 2023.
- Biomarin Pharmaceutical Inc. annual revenue for 2023 was 2.4 B, a 15.42% increase from 2022.
- Biomarin Pharmaceutical Inc. annual revenue for 2022 was 2.1 B.
Biomarin Pharmaceutical Inc. (BMRN) — Frequently Asked Questions
Biomarin Pharmaceutical Inc. (BMRN) is a publicly traded US company. It has a market capitalization of $11.09B. In fiscal 2025 it reported revenue of $3.22B and net income of $349M. Explore BMRN's stock price, financial statements, earnings history, margins and key ratios below.
What is Biomarin Pharmaceutical Inc.'s market cap?
Biomarin Pharmaceutical Inc. (BMRN) has a market capitalization of $11.09B.
What is the BMRN stock price?
BMRN trades at $56.17 (-3.00% on the day).
How much revenue does Biomarin Pharmaceutical Inc. make?
Biomarin Pharmaceutical Inc. reported revenue of $3.22B in fiscal 2025.
Is BMRN profitable?
In fiscal 2025, Biomarin Pharmaceutical Inc. reported net income of $349M.